Mechanopriming for cell engineering

用于细胞工程的机械引发剂

基本信息

  • 批准号:
    10737574
  • 负责人:
  • 金额:
    $ 50.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-06-15 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

Project Summary Cell reprogramming represents a major advancement in biology, and has wide applications in regenerative medicine, disease modeling and drug screening. Somatic cells such as fibroblasts can be directly converted into induced neuronal (iN) cells via the forced expression of three transcription factors: Ascl1, Brn2 and Myt1l (BAM). However, a major challenge of cell reprogramming, especially iN reprogramming, is the low reprogramming efficiency, which has limited the translation of this technology for biomedical applications. Biophysical factors from the microenvironment have been shown to regulate many aspects of cell functions such as cell growth, migration and differentiation. Recently, we have shown that mechanical deformation of cell nucleus through microfluidic channels can promote open chromatin structure and enhance cell reprogramming, yet the underlying mechanisms are not well understood. Based on our recent findings, we hypothesize that a mechanopriming process such as mechanical squeezing of cell nucleus can induce NL reorganization and a permissive chromatin state to facilitate the activation of neuronal genes in the heterochromatin of fibroblasts, which promotes iN reprogramming and CRISPR- mediated gene editing/activation. To test our hypothesis, we propose three Specific Aims: (1) To investigate how nuclear deformation modulates the epigenetic state to enhance iN reprogramming; (2) To determine the role of nuclear lamina in mediating nuclear deformation-induced LAD dissociation, epigenetic changes and iN reprogramming; (3) To investigate the enhancement of CRISPR-mediated neuronal gene activation by mechanical squeezing. We have assembled a multidisciplinary team with expertise on cell engineering, microdevice fabrication, high-throughput genomic and epigenomic analysis, neuroscience, biosensors and CRISPR gene editing to work together and investigate the mechanical regulation of epigenetic state and cell reprogramming. We propose to optimize a high-throughput microfluidic device, further investigate the causative mechanisms and profile the genome-wide site-specific epigenetic changes induced by nuclear deformation, which can provide a rational basis for the design of site-specific gene editing for cell engineering. Accomplishment of this project will advance our understanding of how biophysical factors regulate cell reprogramming and the epigenetic state, and unravel new mechanisms of cell fate determination, which will have wide applications in gene editing, cell and tissue engineering, disease modeling and drug discovery.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Song Li其他文献

Song Li的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Song Li', 18)}}的其他基金

Combination Therapy for Pancreatic Cancer
胰腺癌的联合治疗
  • 批准号:
    10581174
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
Nanoparticles-mediated combination therapy for breast cancer
纳米颗粒介导的乳腺癌联合疗法
  • 批准号:
    10617544
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
Multimodal wireless electrical stimulation for tissue regeneration
用于组织再生的多模式无线电刺激
  • 批准号:
    10615764
  • 财政年份:
    2022
  • 资助金额:
    $ 50.84万
  • 项目类别:
Study of Interleukin 33 as a new immunotherapy of lung cancer
白细胞介素33作为肺癌新型免疫疗法的研究
  • 批准号:
    10703786
  • 财政年份:
    2022
  • 资助金额:
    $ 50.84万
  • 项目类别:
Regulation of cell reprogramming by matrix stiffness
通过基质硬度调节细胞重编程
  • 批准号:
    10281141
  • 财政年份:
    2021
  • 资助金额:
    $ 50.84万
  • 项目类别:
Regulation of cell reprogramming by matrix stiffness
通过基质硬度调节细胞重编程
  • 批准号:
    10491279
  • 财政年份:
    2021
  • 资助金额:
    $ 50.84万
  • 项目类别:
Regulation of cell reprogramming by matrix stiffness
通过基质硬度调节细胞重编程
  • 批准号:
    10687264
  • 财政年份:
    2021
  • 资助金额:
    $ 50.84万
  • 项目类别:
Study of Interleukin 33 as a new immunotherapy of lung cancer
白细胞介素33作为肺癌新型免疫疗法的研究
  • 批准号:
    10442707
  • 财政年份:
    2019
  • 资助金额:
    $ 50.84万
  • 项目类别:
Study of Interleukin 33 as a new immunotherapy of lung cancer
白细胞介素33作为肺癌新型免疫疗法的研究
  • 批准号:
    10202507
  • 财政年份:
    2019
  • 资助金额:
    $ 50.84万
  • 项目类别:
Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy
用于术后癌症免疫治疗的血小板介导的检查点抑制剂递送
  • 批准号:
    10668316
  • 财政年份:
    2019
  • 资助金额:
    $ 50.84万
  • 项目类别:

相似海外基金

Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
  • 批准号:
    MR/Y019458/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Research Grant
Fabrication and Evaluation of Poly(glycerol sebacate) based small diameter vascular graft as a potent substitution for autologous vessels
基于聚(甘油癸二酸酯)的小直径血管移植物作为自体血管有效替代品的制造和评估
  • 批准号:
    2897580
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Studentship
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head
自体骨髓抽吸浓缩液治疗股骨头坏死
  • 批准号:
    10658324
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
识别治疗慢性术后眼痛的自体血清泪液的多模式生物标志物
  • 批准号:
    10794761
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
SBIR Phase II: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts
SBIR II 期:可注射蛋白质基质,增强自体脂肪移植物的稳定性
  • 批准号:
    2304430
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Cooperative Agreement
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
  • 批准号:
    MR/X00466X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Fellowship
Application of Autologous Connective Tissue Sheets Created in Patients' Bodies to Pediatric Cardiac Valvuloplasty and Development of Dedicated Molds
患者体内自体结缔组织片在小儿心脏瓣膜成形术中的应用及专用模具的开发
  • 批准号:
    23K15543
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
SBIR 第二阶段,主题 429:自体和同种异体细胞治疗制造的新范式
  • 批准号:
    10976161
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia
计划对小唾液腺来源的自体 MSC 进行 I 期研究,以预防长期辐射引起的口干症
  • 批准号:
    10720234
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
  • 批准号:
    10721983
  • 财政年份:
    2023
  • 资助金额:
    $ 50.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了